Factors Related to 6-Minute Walk Distance in Pulmonary Arterial Hypertension
Open Access
- 30 July 2025
- journal article
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49 (1) , 1-9
Abstract
Objective: The 6-minute walk test is the most commonly used tool for evaluating prognosis in patients withpulmonary arterial hypertension (PAH). This study aims to identify the parameters associated with 6-minutewalk distance (6MWD) and its changes over time.Methods: Sixty-three patients diagnosed with PAH or chronic thromboembolic pulmonary hypertensionbetween January 2005 and January 2013 were included in the study. Demographic, clinical, echocardiographic, hemodynamic data, and initial and follow-up 6MWD were recorded. The 6MWD cut-off wasdetermined based on previous studies. Patients were then categorized into groups based on their initial6MWD: ≥ 332 m or < 332 m.Results: Patients were followed up for 31.56 ± 15.07 months. In those with a 6MWD < 332m, diffusingcapacity of the lungs for carbon monoxide (DLCO) (P = .040), estimated glomerular filtration rate (P = .018),and partial arterial oxygen pressure (PaO2) (P = .024) were significantly lower, whereas age (P = .016), rightatrial pressure (P = .034), the frequency of pericardial effusion (P = .004), and mortality (P = .020) weresignificantly higher. Low DLCO was identified as an independent predictor of walking less than 332 meters(P = .048). In the subgroup analysis, among idiopathic PAH (IPAH) patients, DLCO (P = .024) was lower inthose with 6MWD < 332 m. In patients with scleroderma-associated PAH (SSc-PAH), systolic pulmonaryartery pressure (sPAP) (P = .018), and mean PAP (p = 0.034) were higher in patients with 6MWD < 332 m.When the change in 6MWD (Δ6MWD) was evaluated based on the difference between the initial 6MWDand at the end of the follow-up period, DLCO was lower in the group with a decreased 6MWD (P < .001).Conclusion: The study identified higher DLCO as an independent predictor of 6MWD ≥ 332 m and itsimprovement over time. In IPAH, 6MWD is more closely associated with DLCO and PaO2, whereas in SScPAH, PAPs play a more significant role.Cite this article as: Yurtseven E, Özcan S, Karadağ B, Öngen HG, Öngen Z. Factors related to 6-minute walk distance in pulmonaryarterial hypertension. Cerrahpaşa Med J 2025, 49, 0015, doi: 10.5152/cjm.2025.25015.Keywords
This publication has 24 references indexed in Scilit:
- Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial HypertensionChest, 2021
- Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registryThe Journal of Heart and Lung Transplantation, 2020
- Six-Minute Walk TestChest, 2020
- Anaemia, iron homeostasis and pulmonary hypertension: a reviewInternal and Emergency Medicine, 2020
- Lung function in relation to six-minute walk test in pulmonary hypertensionEuropean Clinical Respiratory Journal, 2020
- The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registryClinical Research in Cardiology, 2018
- Systemic sclerosisThe Lancet, 2017
- Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?JACC, 2012
- Comparison of Baseline Predictors of Prognosis in Pulmonary Arterial Hypertension in Patients Surviving ≤2 Years and Those Surviving ≥5 Years After Baseline Right-Sided Cardiac CatheterizationThe American Journal of Cardiology, 2012
- Reduced exercise capacity in systemic sclerosis patients without pulmonary involvementScandinavian Journal of Rheumatology, 2007